Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

@article{Schwarz2009ImmunogenicityAT,
  title={Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.},
  author={Tino F Schwarz and Marek Spaczynski and Achim Schneider and Jacek Wysocki and Andrzej Galaj and Pamela Perona and Sylviane M Poncelet and Toufik Zahaf and Karin Hardt and Dominique J Descamps and Gary O. Dubin},
  journal={Vaccine},
  year={2009},
  volume={27 4},
  pages={581-7}
}
The immunogenicity and safety of an HPV-16/18 AS04-adjuvanted vaccine were assessed in women aged 26-55 years and compared with women aged 15-25 years in a Phase III, non-randomised, open-label, age-stratified study. Overall the vaccine was well tolerated and 100% seropositivity was achieved 1 month after the third dose in all age groups. There was a high correlation between HPV-16 and HPV-18 antibody levels (IgG) in cervicovaginal secretions and sera, regardless of age. The HPV-16/18 AS04… CONTINUE READING